MaaT Pharma Presents Positive Phase 1b/2a Study Results in Acute Myeloid Leukemia Patients

Read

Previous PostHERACLES: A Phase II single-arm prospective study to assess the efficacy of Fecal Microbiota Transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-hsct
Next PostMaaT Pharma Announces Positive DSMB Safety Review and Continuation of its Phase II HERACLES Study in Acute GvHD

MaaT Pharma dans les médias MaaT Pharma in the News